Pipeline activity
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Pressure score
65
Momentum score
24
Why This Matters
Roche is a direct competitive threat because it has a Phase III program in Oncology · Lung Cancer (Pipeline activity) and could narrow AstraZeneca's development lead.
Competitive Assessment
- Threat type
- direct competitor
- Development stage
- Phase III
- Stage gap
- Stage comparison unavailable — competitor development phase not fully evidenced.
- Market share risk
- Late-stage competitor could compress launch window and payer leverage before approval.
Strategic Action
Align with signal posture: monitor. Monitor direct competitor activity and refresh competitive intelligence after material readouts.
Overlap Analysis
Source Analysis
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Oncology · KRAS G12C Non-Small Cell Lung Cancer · Trial Update · Divarasib's superior efficacy positions it as a potential new standard of care, challenging current treatments like sotorasib and adagrasib.
Source: Roche
View source documentRelated Signal
AstraZeneca Launches AI Study for Lung Cancer Risk Stratification
Open signalCompetitor Position
Competitor race
Pressure ranking for this signal's competitive set
Position: #1 of 2
Roche
2 competitive findings
Top program: Pipeline activity
- Pressure
- 66
- Momentum
- 24
- Threat
- direct competitor
- Stage
- Phase III
66RocheMediumPipeline activity·Phase III
Pfizer
2 competitive findings
Top program: Pipeline activity
- Pressure
- 34
- Momentum
- 5
- Threat
- adjacent competitor
- Stage
- Stage unknown
34PfizerLowPipeline activity·Stage unknown